Dr. Shroyer’s research is focused on the discovery and validation of cancer biomarkers with the underlying goal of discovering and validating novel diagnostic, prognostic, and predictive biomarkers and to uncover targetable mechanisms that drive chemoresistance. In addition, he serves as the Director of the Research Histology Core Laboratory and is the scientific co-director of the Stony Brook Biobank. Over the course of his scientific career, Dr. Shroyer invented the method of DNP labeling of nucleic acid probes, was a pioneer in the development of methods for in situ hybridization of mRNAS in the early 1980s and was the first to report the molecular analysis of x-chromosome inactivation in archival tissues as a marker of clonality. He also participated in the early validation of tyramide-based signal amplification technology for in situ hybridization and high sensitivity immunohistochemistry. Since his recruitment to Stony Brook Medicine in 2007, Dr. Shroyer has focused in uncovering molecular mechanisms which drive fundamental properties of the most aggressive forms of human cancer, including pancreatic ductal adenocarcinoma (PDAC). Co-directed by Dr. Luisa Escobar-Hoyos, the lab has leveraged mass spectrometry and immunohistochemical approaches to establish that keratin 17 (K17) is more accurate than clinicopathologic assessment to predict patient survival of patients with multiple types of carcinomas. Moving beyond K17 as a prognostic biomarker, they further identified the key molecular mechanisms through which K17 promotes tumor growth as a nuclear shuttle of tumor suppressor proteins and that it reprograms the metabalome to promote pyrimidine biosynthesis. The lab has established functional domains that mediate K17’s ability to serve as a nuclear shuttle, providing a rational basis for the development of novel pharmacologic approaches in PDAC. Dr. Shroyer's team has strong collaborations throughout Stony Brook University and with basic and translational research scientists at academic institutions throughout the United States that are providing technical and scientific support for their work in cancer metabolomics, bioinformatics, and in the study of post-translational modifications that mediate K17 solubility in cancer and have tremendous experience with orthotopic and transgenic mouse models of pancreatic cancer, the development of PDAC organoid cultures and patient-derived xenografts, and RNA-Seq data analysis and predictive modeling. The lab also serves as one of Renaissance School of Medicine's most impactful cancer research training sites for undergraduate, graduate, and medical students, as well as for research postdoctoral fellows and clinical research fellows.

 

Awards: Pancreatic Cancer Action Network Translational Research Award (2018-2019); Cited by Medscape for senior authorship of the most widely read primary research paper in the field of Pathology (December 2017), Best Doctors in America (2009-2014, 2017); Recognition for senior authorship of one of Human Pathology’s top 10 cited articles (2009), Lucien J. Rubinstein Award for the Best Paper on Neuro-oncology (1998); NIH Shanon Award (1992); Robert H. Fennell, Jr., M.D. Award, Department of Pathology, UCHSCC (1992);  Edgar and Marion Adler Scholar Award (185-187)

​

Bibliography: https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/47427615/

 

Dr. Shroyer’s ScieENcv